Pfizer's Zoetis Subsidiary Files IPO
Zoetis, a subsidiary of Pfizer, filed a registration statement with the US Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock.
Zoetis, a subsidiary of Pfizer, filed a registration statement with the US Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock, Pfizer announced in an Aug. 13, 2012 press release.
Details of the IPO, including the price and number of shares, have not yet been determined. The offering, however, is expected to represent an ownership stake of up to 20%.
Prior to the IPO completion, which is targeted for the first half of 2013, Pfizer will transfer its animal health business to Zoetis. The Pfizer Animal Health business unit works to discover, develop, manufacture, and commercialize animal health medicines and vaccines for both livestock and companion animals.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
